Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesThe Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy
Clinical and Experimental Hypertension, 07/23/08
Ruilope LM et al. - Angiotensin II receptor blockers (ARBs) are highly efficacious, persistent, well-tolerated antihypertensive agents, with additional benefits in comorbid hypertension, CV pathologies, end-organ damage, and, in diabetes, diabetic nephropathy or metabolic syndrome. ARBs decrease overall risk of CV and end-organ disease, CVD-related mortality, and cerebrovascular events in patients with hypertension.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Sponsor
Article Search
Sponsor
Sponsor